The clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence provide a framework for clinical decision making by clinicians and consumers in a range of service settings involved in the delivery of treatment with long acting depot buprenorphine products.
A brief summary guideline is available: Brief Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence.
The guidelines were developed by Professors Nicholas Lintzeris and Adrian Dunlop, and Debbie Masters, based on the available evidence and experience from clinical trials.
The guidelines are intended to be updated in the future to reflect the experiences of clinicians and patients using depot buprenorphine.
For additional advice on selected topics please see the Depot buprenorphine clinical guidelines addenda
The guidelines should be read in conjunction with the NSW Clinical Guidelines: Treatment of Opioid Dependence.
